Synthekine
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1505 Obrien Dr, Menlo Park, California, ...Phone Number
(650) 271-9888Website
www.synthekine.comRevenue
$16.9 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About Synthekine
Founded in 2019, headquartered in Menlo Park, California, Synthekine is an engineered cytokine therapeutics company.Explore more
Synthekine Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Synthekine your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Synthekine launches new products
Check if Synthekine has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Synthekine has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Synthekine recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Synthekine
Click to see if Synthekine had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Synthekine, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Synthekine is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Synthekine
Compare insights from companies similar to Synthekine, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Synthekine is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Synthekine is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Synthekine.
Synthekine financials insights
Gather financial insights about Synthekine, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$82M
2021
Series B
$107.5M
2023
Series C
$100M
Synthekine Tech Stack
A closer look at the technologies used by Synthekine
See more technologies
Most Recent Scoops
Hiring Plans
Synthekine has more open roles in Operations than it has had at any time in the past 12 months.
Hiring Plans
Open Position
Person-Based
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Partnership, Medical Research, Pharmaceuticals, Clinical Operations
Synthekine News & Media
Synthekine Presents Positive Initial Results from Phase 1 Clinical Trial of CD19 CAR-T (SYNCAR-001) and Orthogonal IL-2 (STK-009) Combination Therapy for Treatment of Hematologic Malignancies at ASH 2024 Annual Meeting
MENLO PARK, Calif.--(BUSINESS WIRE)--Synthekine Inc., an engineered cytokine therapeutics company, today announced positive initial results from a first-in-human Phase 1 study (NCT05665062) of SYNCAR-001 + STK-009 for the treatment of relapsed or refractory CD19+ hematologic malignancies. In the results presented from 8 patients treated in the dose escalation portion of the study with a fixed SYNCAR-001 infusion of 30M cells and STK-009 doses ranging from 1.5 to 6 mg, this combination therapy wSynthekine to Present Preclinical Data for CD19 CAR-T (SYNCAR-001) Empowered by Orthogonal IL-2 (STK-009) Without Lymphodepletion at American College of Rheumatology (ACR) Convergence 2024
MENLO PARK, Calif.--(BUSINESS WIRE)--Synthekine Inc., an engineered cytokine therapeutics company, today announced promising preclinical results with the murine version of its STK-009 + SYNCAR-001 program will be presented at the American College of Rheumatology (ACR) Convergence 2024 in Washington, D.C. This regimen demonstrated potential to treat autoimmune diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), without requiring lymphodepletion. Preclinical findinSynthekine Announces Presentation of New Translational Data from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
MENLO PARK, Calif.--(BUSINESS WIRE)--Synthekine Inc., an engineered cytokine therapeutics company, today presented positive translational results from the Phase 1a dose escalation portion of a Phase 1a/1b clinical trial of its first-in-class α/β-IL-2R biased partial agonist, STK-012, at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting in Houston. STK-012 is engineered to selectively stimulate CD25+ antigen-activated T cells, which are associated with potent anti-tumor activity
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Synthekine
Sign Up For FreeTo access detailed company insights
Founded in 2019, headquartered in Menlo Park, California, Synthekine is an engineered cytokine therapeutics company.... Read More
